R. Guardeño

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2021 · 76 citations

Medicine, Oncology, Pharmacology +17

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in <i>KRAS</i> wild‐type tumor cells

Cristina Oliveras‐Ferraros, Alejandro Vázquez‐Martín, Sílvia Cufí et al. · Journal of Cellular Biochemistry · 2010 · 47 citations · Full text

Medicine, Genetics, Oncology +17

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Daniel V.T. Catenacci, Yoon‐Koo Kang, Anwaar Saeed et al. · Journal of Clinical Oncology · 2021 · 36 citations

Medicine, Oncology, Cancer Pharmacology +9

Clinical guideline SEOM: hepatocellular carcinoma

Javier Sastre, Jesús García‐Foncillas, R. Guardeño et al. · Clinical & Translational Oncology · 2015 · 32 citations · Full text

Medicine, Oncology, Radiology +17